Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK2D | Q13557 | 3/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 7/20 | 0.37 |
| ▸ | CNR1 | P21554 | 3/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
| ▸ | PRKCB | P05771 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | LYN | P07948 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6073315 | 0.92 | CAMK2D (0.42) | CAMK2DDYRK1AALDH1A1CNR2CNR1 | |
| SCHEMBL4654813 | 0.89 | KMT2A (0.44) | CAMK2DDYRK1AALDH1A1CNR2CNR1 | |
| SCHEMBL6073363 | 0.86 | CAMK2D (0.51) | CAMK2DDYRK1ACNR2CNR1 | |
| SCHEMBL4653711 | 0.81 | P2RX3 (0.41) | CAMK2DDYRK1AALDH1A1CNR2CNR1 | |
| SCHEMBL29324307 | 0.77 | LMNA (0.53) | CAMK2DCNR2 | |
| SCHEMBL9319939 | 0.76 | ALDH1A1 (0.42) | CAMK2DALDH1A1TDP1 | |
| SCHEMBL4656142 | 0.75 | LMNA (0.53) | CAMK2DDYRK1ACNR2CNR1TDP1 | |
| SCHEMBL4176799 | 0.74 | ALDH1A1 (0.43) | CAMK2DALDH1A1CNR2 | |
| SCHEMBL5711757 | 0.73 | HSD17B10 (0.42) | CAMK2DALDH1A1CNR2 | |
| SCHEMBL4654929 | 0.73 | CAMK2D (0.37) | CAMK2DDYRK1ACNR2CNR1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7018611-B2 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-03-28 | — | — | US | disclosed |
| US-6743412-B2 | ADMINISTERING TO TREAT RHEUMATOID ARTHRITIS, CANCER, RESTENOSIS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-6689337-B2 | TARGETING MOIETY OF A QUINOLONE NONPEPTIDE BOUND TO A CHELATOR AND ALSO BINDS TO A RECEPTOR THAT IS UPREGULATED DURING ANGIOGENESIS; IMAGING COMPOUNDS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-02-10 | — | — | US | disclosed |
| US-6683163-B2 | MONITORING ANGIOGENESIS FACTOR | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-01-27 | — | — | US | disclosed |
| US-20030232053-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MEDICAL IMAGING, INC. | 2003-12-18 | — | — | US | disclosed |
| US-20030124120-A1 | Quinolone vitronectin receptor antagonist pharmaceuticals | HARRIS THOMAS D (US) | 2003-07-03 | — | — | US | disclosed |
| US-20030113336-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS HOLDINGS, INC. | 2003-06-19 | — | — | US | disclosed |
| US-20030103898-A1 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | LANTHEUS MEDICAL IMAGING, INC. | 2003-06-05 | — | — | US | disclosed |
| US-6524553-B2 | A compound, comprising: a targeting moiety and a chelator, wherein the targeting moiety is bound to the chelator, is a qinolone nonpeptide, and binds to a receptor that is upregulated during angiogenesis | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-02-25 | — | — | US | disclosed |
| US-6511649-B1 | Chemotherapeutic, a radiosensitizer agent, and a targeting moiety bound to chelator and is a quinolone nonpeptide that binds to a receptor; therapeutically effective radioisotope or diagnostically effective imageable moiety; cancer | LANTHEUS MI REAL ESTATE, LLC | 2003-01-28 | — | — | US | disclosed |
| US-6511648-B2 | Diagnosis, therapy cancer | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-28 | — | — | US | disclosed |
| US-20020182147-A1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | LANTHEUS MI REAL ESTATE, LLC | 2002-12-05 | — | — | US | disclosed |
| US-20020061909-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MI REAL ESTATE, LLC | 2002-05-23 | — | — | US | disclosed |
| US-20020015680-A1 | QUINOLONE VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | CITIZENS BANK, N.A. | 2002-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030124120-A1 | Quinolone vitronectin receptor antagonist pharmaceuticals | ADGRF1, QRFPR, ADGRE5 | CAMK2D 1759/4885DYRK1A 3511/4885DRD2 326/4885 |
| US-20030103898-A1 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | TNNI3, ASGR1, TNNT2 | CAMK2D 2093/4885DYRK1A 2996/4885DRD2 3023/4885 |
| US-20020015680-A1 | QUINOLONE VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | ADGRF1, QRFPR, ADGRE5 | CAMK2D 1759/4885DYRK1A 3511/4885DRD2 326/4885 |
| US-20030232053-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | CAMK2D 1194/4885DYRK1A 3347/4885DRD2 456/4885 |
| US-20030113336-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | CAMK2D 1359/4885DYRK1A 3295/4885DRD2 622/4885 |
| US-20020061909-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | CAMK2D 1194/4885DYRK1A 3347/4885DRD2 456/4885 |
| US-20020182147-A1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | ADGRF1, RXFP1, VCAM1 | CAMK2D 1194/4885DYRK1A 3347/4885DRD2 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.